Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas

被引：107

作者：

Feldman, A. L. ^{[1
]}

Sun, D. X. ^{[1
]}

Law, M. E. ^{[1
]}

Novak, A. J. ^{[2
]}

Attygalle, A. D. ^{[3
]}

Thorland, E. C. ^{[1
]}

Fink, S. R. ^{[1
]}

Vrana, J. A. ^{[1
]}

Caron, B. L. ^{[1
]}

Morice, W. G. ^{[1
]}

Remstein, E. D. ^{[1
]}

Grogg, K. L. ^{[1
]}

Kurtin, P. J. ^{[1
]}

Macon, W. R. ^{[1
]}

Dogan, A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Hematol, Rochester, MN 55905 USA

[3] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England

来源：

LEUKEMIA | 2008年 / 22卷 / 06期

关键词：

peripheral T-cell lymphoma; Syk; tyrosine kinase; phosphorylation;

D O I：

10.1038/leu.2008.77

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n = 6) and flow cytometry on cell suspensions (n = 4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL.

引用

页码：1139 / 1143

页数：5

共 50 条

[31] Novel therapies in peripheral T-cell lymphomas
Hilary M. O’Leary
Kerry J. Savage
Current Oncology Reports, 2008, 10 : 404 - 411
[32] THE PERIPHERAL T-CELL LYMPHOMAS COME OF AGE
NEIMAN, RS
MAYO CLINIC PROCEEDINGS, 1986, 61 (06) : 504 - 506
[33] Pathology and biology of peripheral T-cell lymphomas
de Leval, Laurence
Gaulard, Philippe
HISTOPATHOLOGY, 2011, 58 (01) : 49 - 68
[34] Novel therapies for peripheral T-cell lymphomas
Shustov, Andrei
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (03) : 173 - 187
[35] PATHOLOGY OF PERIPHERAL T-CELL LYMPHOMAS AND LEUKEMIAS
WATANABE, S
HEMATOLOGICAL ONCOLOGY, 1986, 4 (01) : 45 - 58
[36] Novel therapies in peripheral T-cell lymphomas
O'Leary H.M.
Savage K.J.
Current Hematologic Malignancy Reports, 2008, 3 (4) : 213 - 220
[37] Pathology and pathophysiology of peripheral T-cell lymphomas
Gaulard, P.
de Leval, L.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S6 - S7
[38] Peripheral T-cell lymphomas: diagnosis and management
Dearden, CE
Foss, FM
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (06) : 1351 - +
[39] ABERRANT PHENOTYPES IN PERIPHERAL T-CELL LYMPHOMAS
HASTRUP, N
RALFKIAER, E
PALLESEN, G
JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (04) : 398 - 402
[40] Molecular genetics of peripheral T-cell lymphomas
Piccaluga, Pier Paolo
Tabanelli, Valentina
Pileri, Stefano A.
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (03) : 219 - 226

← 1 2 3 4 5 →